Pharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal
|
|
- Marjorie Dalton
- 5 years ago
- Views:
Transcription
1 Pharmacokinetics Processes, Mathematics, and Applications Second Edition Peter G. Welling Institut de Recherche Jouveinal ACS Professional Reference Book American Chemical Society Washington, DC
2 Contents Preface xiii DRUG ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION 1 1. Drug Absorption, Distribution, Metabolism, and Excretion 3 Different Approaches to Pharmacokinetics / 4 References / 9 2. Drug Transport 11 The Cell Membrane / 11 Membrane Transport / 12 Summary / 17 References / Parenteral Routes of Drug Administration 19 Intraarterial Administration / 20 Intrathecal Administration / 20 Intravenous Administration / 21 Intramuscular Administration / 23 Buccal Administration / 24 Intranasal Administration / 25 Inhalation / 28 Transdermal Administration / 31 Vaginal Administration / 37 Rectal Administration / 38 Summary / 39 References / 40 VII
3 S: PROCESSES, MATHEMATICS, AND APPLICATIONS! 4. Enteral Routes of Drug Administration 43 Physiology of the GI Tract / 43 GI Structure and Motility Factors / 45 Gastrointestinal Blood Flow in Relation to Drug Absorption / 50 Special Transport Mechanisms / 51 Animal Models for Oral Drug Absorption / 52 Summary / 59 References / Factors Influencing Absorption and Bioavailability After Enteral Administration 63 Metabolism in the Gut / 64 Metabolism in the Lung / 65 Hepatic Metabolism and the First-Pass Effect / 66 Enterohepatic Circulation / 69 Factors Influencing the First-Pass Effect / 71 Summary / 73 Problems / 73 References / Physicochemical and Formulation Factors Affecting Drug Absorption 75 Chemical Factors / 75 Physical Factors / 76 Formulation Factors / 78 In Vitro-In Vivo Correlations / 80 Excipients / 81 Coated Tablets / 82 Controlled-Release Formulations / 82 Absorption Enhancers / 89 Summary / 93 References / Clinical Factors and Interactions Affecting Drug Absorption 95 Influence of GI Disease on Drug Absorption / 95 Drug-Drug Interactions Affecting Absorption / 100 Drug-Food Interactions Affecting Absorption / 105 Conclusions / 116 Summary / 116 References / Drug Distribution 119 Distribution-Concentration Relationships / 120 Capillary Permeability / 121 Perfusion and Diffusion Effects / 122 Binding of Drugs to Tissues / 124
4 Intravascular and Extravascular Drug Binding / 128 Penetration of Drug into the Central Nervous System / 135 Methods of Determining Drug Distribution / 139 Summary / 141 Problems / 142 References / Drug Metabolism 145 Sites of Drug Metabolism / 145 Mechanisms of Drug Metabolism / 147 Species, Sex, and Age Differences / 156 Steric Factors / 159 Enzyme Induction / 159 Enzyme Inhibition / 160 Summary / 160 References / Effect of Liver Disease on Drug Metabolism and Pharmacokinetics 163 Function and Structure of the Liver / 164 Types and Severity of Liver Disease / 164 Effects on Pharmacodynamics and Pharmacokinetics / 165 Examples of Effects of Liver Disease on the Pharmacokinetics of Some Drug Classes / 169 Conclusions / 171 Summary / 172 References / Renal Excretion 175 Structure and Function of the Kidney / 175 Clearance / 178 Renal Clearance and Plasma Clearance / 179 Relationship Among Clearance, Drug Elimination Rate, and Half-Life / 182 Summary / 184 Problems / 184 References / Drug Elimination in Renal Impairment 187 Methods of Measuring Renal Function / 188 Use of Creatinine Clearance to Predict the Effect of Renal Impairment on Drug Elimination / 190 Methods of Dosage Adjustment / 191 Maintenance of Patients with End-Stage Kidney Disease / 194 Summary / 195 Problems / 196 References / 197
5 THE MATHEMATICS OF PHARMACOKINETICS The One-Compartment Open Model with Intravenous Dosage 201 The One-Compartment Open Model with Bolus Intravenous Injection / 202 The Trapezoidal Rule / 207 Urinary Excretion Kinetics / 210 Construction of Sigma-Minus Plots / 211 Zero-Order Drug Input and First-Order Elimination / 213 Summary / 219 Problems / 219 References / The One-Compartment Open Model with First-Order Absorption and Elimination 223 General Aspects of First-Order Absorption and Elimination / 223 Graphical Estimation of Parameters / 226 Other Parameters Associated with First-Order Absorption and Elimination / 230 Drug Absorption Plots / 232 Area Under the Drug-Concentration Curve jauc) / 234 Absorption Lag Time / 236 Cumulative Urinary Excretion of Unchanged Drug / 237 Summary / 241 Problems / 242 References / Multiple-Dose Kinetics 245 Drug Accumulation with Repeated Doses / 245 Drug Accumulation Rate / 250 The Degree of Drug Accumulation with Repeated Dosing and the Loading Dose Required To Instantaneously Achieve Steady-State Levels / 252 First-Order Absorption Case / 253 Summary / 256 Problems / 256 References / Metabolite Pharmacokinetics 259 Pharmacokinetics of Metabolite Formation and Elimination / 259 Analysis of Metabolite Concentrations in Plasma, and Urinary Excretion / 262 Resolving the Pharmacokinetics of Metabolite and Parent Drug / 265 Summary / 268 Problems / 268 References / 269
6 17. The Two-Compartment Open Model with Intravenous or Oral Administration 271 The Two-Compartment Model with Bolus Intravenous Injection / 272 Interpretation of Drug-Concentration Profiles in Plasma To Obtain Parameter Estimates / 273 Graphical Estimation of Kinetic Parameters / 276 Derivation of AUC ^~, Plasma Clearance, and Renal Clearance / 278 Volume of Distribution at Equilibrium / 279 Kinetics of Tissue Distribution / 282 Obtaining Parameter Estimates from Urinary Excretion Data / 283 The Two-Compartment Model with First-Order Drug Input / 285 Drug Concentration in the First Compartment / 288 Some Model-Independent Parameters for a Drug that Obeys Two-Compartment Model Kinetics / 292 Summary / 294 Problems / 295 References / Physiological Pharmacokinetic Models 297 Description of Physiological Pharmacokinetic Model / 297 Organ Clearance / 299 Blood Flow Rate-Limited Transport / 300 Membrane-Limited Transport / 305 Experimental Considerations / 306 Summary / 308 Problems / 309 References / Nonlinear Pharmacokinetics 311 Saturable Processes / 311 Expressions Useful in Elimination Kinetics / 313 Obtaining Estimates of V m and K m from Plasma-Level Data / 316 Influence of Saturable Kinetics on Drug Elimination, Area Under the Drug-Concentration Curve, and First-Pass Effect / 318 Summary / 321 Problems / 321 References / 322 APPLICATIONS OF PHARMACOKINETICS IN DRUG DISCOVERY AND DEVELOPMENT Pharmacokinetics and Toxicokinetics 325 Pharmacokinetics and Pharmacodynamics / 325 Toxicokinetics and Toxicodynamics / 326 Technical Differences Between Pharmacokinetics and Toxicokinetics / 326
7 PH \RMACOkl\ETK V PRO< FSSCS, MATHEMATICS. AND APPLIC ATIONS Philosophical Differences Between Pharmacokinetics and Toxicokinetics / 328 Conclusions / 329 Summary / 329 References / Role of Pharmacokinetics in Drug Discovery and Development 331 Regulatory Submissions / 331 Drug Discovery and Development / 332 Regulatory Submissions and Drug Labeling / 340 Postsubmission and Postmarketing Studies / 341 Conclusions / 341 Summary / 342 References / Integration of Pharmacokinetics into Research and Development 343 The R&D Sequence / 343 Statement of the Problem / 344 The Alternatives / 344 Comparison of the Alternatives / 345 Conclusions / 350 Summary / 352 Reference / 353 APPENDIXES 355 Appendix I: Computer Methods and Software for Pharmacokinetic Data Analysis 357 Appendix II: Worked Answers to Problem Sets 359 Appendix III: Nomenclature 373 Appendix IV: Glossary 377 INDEX 381
BASIC PHARMACOKINETICS AND PHARMACODYNAMICS
BASIC PHARMACOKINETICS AND PHARMACODYNAMICS An Integrated Textbook and Computer Simulations SARA ROSENBAUM ~ WILEY A lohn WILEY & SONS, INC., PUBLICATION CONTENTS Preface 1 Introduction to Pharmacokinetics
More informationKING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D
KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D BY Mohammed Mahmoud Academic Session 147-8 1 st Semester (Semester No 71)
More informationPharmacokinetic & Pharmacodynamic Data Analysis
Pharmacokinetic & Pharmacodynamic Data Analysis CONCEPTS AND APPLICATIONS 4TH EDITION REVISED AND EXPANDED Table of Contents 1. 1.1 1.2 1.3 1.4 1.5 2. 2.1 2.2 2.2.1 2.2.2 2.2.3 2.2.4 2.2.5 2.2.6 2.2.7
More informationMODERN MEDICINAL CHEMISTRY
MODERN MEDICINAL CHEMISTRY JOHN B. TAYLOR, B.SC.,D.I.C.,PI..D., Senior Vice President, Central Research, Rhone-Poulenc Rorer, Dagenham Research Centre, Essex and PETER D. KENNEWELL, B.A.,M.A.,Ph.D., Scientific
More informationPHARMACOKINETICS. Dr. M.Mothilal Assistant professor
PHARMACOKINETICS Dr. M.Mothilal Assistant professor 1 OVERVIEW Basic considerations in pharmacokinetics Compartment models One compartment model Assumptions Intravenous bolus administration Intravenous
More informationBIOPHARMACEUTICS AND PHARMACOKINETICS. University of Alcalá. Academic year 2016/17 3 rd Year 1 st Season
BIOPHARMACEUTICS AND PHARMACOKINETICS Degree in PHARMACY University of Alcalá Academic year 2016/17 3 rd Year 1 st Season COURSE DESCRIPTION Title: Biopharmaceutics and Pharmacokinetics Code: 570014 Degree:
More informationHow do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?
Pharmacokinetics : Basic Principles verview 1. PK : Basic principles and processes 2. Important PK Parameters 3. Modulating PK Parameters 4. PK : Drugs vs. contrast agents Twan Lammers Dept. of Experimental
More informationBIOPHARMACEUTICS AND PHARMACOKINETICS
BIOPHARMACEUTICS AND PHARMACOKINETICS (JULIO 2015) Degree in PHARMACY University of Alcalá Academic year 2015/16 3 rd Year 1 st Season COURSE DESCRIPTION Title: Biopharmaceutics and Pharmacokinetics Code:
More informationHandbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists
Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists
More informationII Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week THEORY
II Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week Solubility: Solubility of solid in liquids, Theory of solution formation. Solubilisation techniques using surfactants,
More informationOral Delivery of Drugs
Oral Delivery of Drugs 1 S E S S I O N O N E O F T I P P R O J E C T Advantages of taking oral drugs Convenient (storage, portability, premeasured dose) economical non-invasive, often safer route requires
More informationApplication of PBPK Models in Assessment of Bioequivalence
Application of PBPK Models in Assessment of Bioequivalence Robert Lionberger, Ph.D. Acting Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation and Research, FDA
More informationStudy (s) Degree Center Acad. Period Grado de Farmacia FACULTY OF PHARMACY 3 Annual PDG Farmacia-Nutrición Humana y Dietética
COURSE DATA Data Subject Code 34081 Name Biopharmacy and Pharmacokinetics Cycle Grade ECTS Credits 10.5 Academic year 2014-2015 Study (s) Degree Center Acad. Period year 1201 - Grado de Farmacia FACULTY
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Complex picture of drug interactions in the body. This slide gives an idea of the complexity of drug disposition. Shown in this slide are many of the steps to getting
More informationINTRODUCTION TO CLINICAL PHARMACY
CHAPTER 1 INTRODUCTION TO CLINICAL PHARMACY Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health, wellness, and disease
More informationINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of
More informationChimica Farmaceutica. Pharmacokinetics and related topics
Chimica Farmaceutica Pharmacokinetics and related topics INTRODUCTION In order to produce its intended effect, a drug must be present at an appropriate concentration in the fluid surrounding the effect
More informationSEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS
SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS Presented by: Ch. Karthik Siva Chaitanya M.Pharm (1 st sem),pharmaceutics UCPSc,KU. 1 Contents: Introduction to noncompartmental pharmacokinetic approach Differences
More informationModern Pharmaceutics. Second Edition, Revised and Expanded. edited by GILBERT S. BANKER University of Minnesota Minneapolis, Minnesota
Modern Pharmaceutics Second Edition, Revised and Expanded edited by GILBERT S. BANKER University of Minnesota Minneapolis, Minnesota CHRISTOPHER T. RHODES : ' University of Rhode Island Kingston, Rhode
More informationBiopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics
Biopharmaceutics Lecture :1 Module Introduction and Introduction to Biopharmaceutics Assist. Lecturer Ali Yaseen Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of
More informationUse of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited
Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs Nikunjkumar Patel, Simcyp Limited IVIVC and Its Components CONVOLUTION VALIDATION DECONVOLUTION MODELS IVIVC
More informationGuideline for Bioequivalence Studies of Generic Products. December 22, 1997
Guideline for Bioequivalence Studies of Generic Products December 22, 1997 Index Section 1: Introduction Section 2: Terminology Section 3: Tests A. Oral conventional dosage forms and enteric coated products
More informationDevelopment of biopharmacy
31/10/2017 1 Development of biopharmacy Expression biopharmaceutics was composed By Gerhard Levy and it was written down by John G. Wagner in a publication from 1961 for the first time. Gerhard Levy Knowledge
More informationThe science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form.
The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form. Three major needs that the formulation into a specific dosage form directly address
More informationLipoidal permeability central to drug ADME Major barriers to drug discovery: dogma surrounding plasma protein binding and tissue concentration
Lipoidal permeability central to drug ADME Major barriers to drug discovery: dogma surrounding plasma protein binding and tissue concentration Lipoidal permeability of typical antagonists / inhibitors
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/016/00-corr-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT
More informationGuideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation
1 2 3 21 July 2016 EMA/CHMP/458101/2016 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling
More informationCHAPTER INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES
1.0 INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES Oral ingestion is the preferred route for administration of therapeutic agents, providing a convenient method of effectively achieving both
More informationThe research work highlights the development and evaluation of. bioavailability of drugs. The buccal route can bypass the first-pass
212 9. Summary, conclusion and recommendation 9.1 Summary and conclusion The research work highlights the development and evaluation of novel transbuccal drug antagonist of Famotidine. route have a rapid
More informationGuidance for Industry
Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products General Considerations DRAFT GUIDANCE This guidance document is being distributed for comment purposes
More informationOfficial Letter from the DOH
Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please
More informationAbstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2
Abstract GastroPlus is a mechanistically based simulation software package that predicts absorption, pharmacokinetics, and pharmacodynamics in humans and animals. GastroPlus modeling and simulation has
More informationInstitute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1
Institute of Pharmaceutical Technology and Biopharmacy University of Pécs 2017. szeptember 22. 1 Pre-discovery Goal: Understand the disease and choose a target molecule. How: Scientists in pharmaceutical
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL BIOAVAILABILTY AND BIOEQUIVALENCE OF VETERINARY MEDICINES This guideline has been prepared to serve as a recommendation to applicants wishing to submit data as evidence of efficacy
More informationFig. 4. A two-compartment pharmacokinetic model.
3.4 Pharmacokinetic (PK) modeling and simulations Noora Sjöstedt, Wilma Kiander, Heidi Kidron 3.4.1 Introduction (Hanna Kortejärvi) Pharmacokinetic modeling and simulations can be performed with different
More informationGuideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation
13 December 2018 EMA/CHMP/458101/2016 Committee for Medicinal Products for Human Use (CHMP) Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation Draft agreed
More informationBiology 137 Introduction to Toxicology Fall Which of the following would enhance the excretion of xenobiotic molecules?
1. Which of the following would enhance the excretion of xenobiotic molecules? A) removal of hydroxyl groups and replacement with hydrogen B) increased hydrophobicity of the molecule, which would allow
More informationQUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS
QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS Guideline Title Quality of Prolonged Release Oral Solid Dosage Forms Legislative basis Directive 75/318/EEC as amended Date of first adoption October
More informationPHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATIONS
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATIONS PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATIONS Principles, Methods, and Applications in the Pharmaceutical Industry
More informationdrug discovery: Where are we now? How did we RSC February 2013
The role of pharmacokinetics in drug discovery: Where are we now? How did we get th here??where are we going? Peter Webborn RSC February 2013 Why conduct PK studies in animals? The primary purpose of pre-clinical
More informationGuideline on quality of oral modified release products
20 March 2014 EMA/CHMP/QWP/428693/2013 Committee for Medicinal Products for Human Use (CHMP) Final Draft Agreed by QWP May 2012 Adoption by CHMP for release for consultation 19 July 2012 Start of public
More informationGuideline on quality of oral modified release products
1 2 3 23 August 2012 EMA/492713/2012 Quality Working Party (QWP) 4 5 Draft Draft Agreed by QWP May 2012 Adoption by CHMP for release for consultation 19 July 2012 Start of public consultion 15 September
More informationConventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC
Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC Nikunj Patel, Senior Research Scientist Simcyp (a Certara Company) AAPS
More informationOrganic Pharmaceutical Chemistry: Prodrugs
Organic Pharmaceutical Chemistry IV 1st Semester, Year 5 (2016-2017) Lecture 1 Organic Pharmaceutical Chemistry: Prodrugs Dr Asim A. Balakit Pharmaceutical Chemistry Dept., College of Pharmacy, Babylon
More informationRole of PBPK based virtual trials modeling in generic product development and regulation
Role of PBPK based virtual trials modeling in generic product development and regulation Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation
More informationPharmacokinetics of PROTEIN DRUGS
Pharmacokinetics of PROTEIN DRUGS PEPTIDE AND PROTEIN DRUGS In this lecture, the general differences in the kinetic behavior of protein drugs relative to that observed with small molecules is emphasized.
More informationToxicokinetic models and their applications
Toxicokinetic models and their applications L. Zivkovic Toxicological Centre, Podgorica, Montenegro, lukazi@hdcg.co.me Abstract. In this paper toxicokinetics was examined. Chemical distribution, absorption
More informationBiopharmaceutics Applications in Drug Development
Biopharmaceutics Applications in Drug Development Edited by Rajesh Krishna Merck & Co., Inc. Rahwav, NJ. USA and Lawrence Yu Center for Drug Evaluation & Research Rockville, MD, USA 4y Springer Contents
More informationInjectable modified release products
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the
More informationEurofins ADME BIOANALYSES Your partner in drug development
Eurofins ADME BIOANALYSES Your partner in drug development Since 1987, you have placed your confidence in us. Our responsibility, to which my staff and I commit, is to consistently provide you with relevant
More informationDraft agreed by Pharmacokinetics Working Party February Adopted by CHMP for release for consultation 23 March 2017
18 October 2018 CPMP/EWP/239/95 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally
More informationGuidance for Industry
Guidance for Industry M4S: The CTD Safety U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research
More informationKEY WORDS Pharmacokinetics, modeler, hands-on, safety, practical class, clinical training.
KEY WORDS Pharmacokinetics, modeler, hands-on, safety, practical class, clinical training. ABSTRACT After swallowing or injecting a drug, the magnitude and duration of drug effects, therapeutic and unwanted,
More informationMechanistic IVIVC Using the Simcyp ADAM Model. Make SCIENCE out of IVIVC
Mechanistic IVIVC Using the Simcyp ADAM Model Make SCIENCE out of IVIVC %Dissolved in vivo % Dissolved/Absorbed %Dissolved/Absorbed Plasma Conc (ng/ml) IVIVC and Its Components IVIVC: A predictive mathematical
More informationRevised guideline on the conduct of bioequivalence studies for veterinary medicinal products
1 2 3 21 April 2017 EMA/CVMP/EWP/016/00-Rev.3 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 6 Revised guideline on the conduct of bioequivalence studies for veterinary medicinal products
More informationDesign and Dosage Form. Dr. Deny Susanti
Design and Dosage Form Dr. Deny Susanti Example 1 Aspirin tablet is stable but not as a liquid dosage form How to design liquid form? Soluble or dispersible aspirin tablets-to be dissolved in water Note:
More informationBiomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics
Review 1. Introduction to AMS 2. Background 3. Intravenous pharmacokinetics 4. HPLC AMS 5. FDA guidance on safety testing of drug metabolites 6. Supplementary information 7. Expert opinion Biomedical accelerator
More informationGuidelines for application of chemical-specific adjustment factors in dose/concentration response assessment
Toxicology 181 182 (2002) 115 120 www.elsevier.com/locate/toxicol Guidelines for application of chemical-specific adjustment factors in dose/concentration response assessment M.E. Meek a, *, A. Renwick
More informationBiomath M263 Clinical Pharmacology
Training Program in Translational Science Biomath M263 Clinical Pharmacology Spring 2014 www.ctsi.ucla.edu/education/training/webcasts Wednesdays 3 PM room 17-187 CHS 4/2/2014 Pharmacokinetics (PK) and
More informationThe 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice
The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability WHO Biowaiver Guideline in Regulatory Practice Dr Kamel IDDIR General Director Medicines and Pharmacy Directorate Berne
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Evaluation of Medicines for Human Use London, 27 July 2005 EMEA/CHMP/89249/2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on the Clinical Investigation
More informationTANZANIA FOOD AND DRUGS AUTHORITY
Doc. No. TFDA/DMC/MCER/---- TANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES ON THERAPEUTIC EQUIVALENCE REQUIREMENTS (Made under Section 52 (1) of the Tanzania Food, Drugs and Cosmetics Act, 2003) First Edition
More informationPK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis
PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis
More informationEVALUATION OF THE SAFETY OF VETERINARY MEDICINAL PRODUCTS FOR THE TARGET ANIMALS
EVALUATION OF THE SAFETY OF VETERINARY MEDICINAL PRODUCTS FOR THE TARGET ANIMALS Guideline Title Evaluation of the Safety of Veterinary Medicinal Products for the Target Animals Legislative Basis Directive
More informationOverview of Recently Approved 505(b)(2) New Drug Applications ( ): Role of Clinical Pharmacology
Regulatory Overview of Recently Approved 505(b)(2) New Drug Applications (2010 2012): Role of Clinical Pharmacology The Journal of Clinical Pharmacology XX(XX) 1 7 2014, The American College of Clinical
More informationIn Vitro-In Vivo Correlation:
In Vitro-In Vivo Correlation: Linking Drug Release to Clinical Performance Yihong Qiu, Ph.D. Abbott Laboratories 51st Land O' Lakes Conference: Bridging Material and Product Quality in Developing Tablet
More informationClinical Pharmacology of Antimicrobials in Children
Clinical Pharmacology of Antimicrobials in Children Joe Standing j.standing@ucl.ac.uk MRC Methodology Fellow & Antimicrobial Pharmacist UCL Institute of Child Health Great Ormond Street Hospital for Children
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL DISSOLUTION This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control
More informationPBPK A Platform for Bridging People & Knowledge in Early Drug Development Club Phase I workshop PBPK: A new Paradigm in Drug Development Neil Miller
PBPK A Platform for Bridging People & Knowledge in Early Drug Development Club Phase I workshop PBPK: A new Paradigm in Drug Development Neil Miller 27 th April 2017 Summary Take home messages PBPK has
More informationBIOEQUIVALENCE: BLOOD LEVEL BIOEQUIVALENCE STUDY
VICH GL 52 (BIOEQUIVALENCE) November 2013 For consultation at Step 4 - Draft 4 BIOEQUIVALENCE: BLOOD LEVEL BIOEQUIVALENCE STUDY Recommended for Consultation at Step 4 of the VICH Process in November 2013
More informationThe Dose: Toxicokinetics for Human Health Risk Assessment
The Dose: Toxicokinetics for Human Health Risk Assessment John C. Lipscomb, PhD, DABT, ATS U.S. Environmental Protection Agency Office of Research and Development National Center for Environmental Assessment
More informationMultisource (generic) pharmaceutical products: guidelines on registration requirements to establish
Annex 7 Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability 1 1. Introduction 134 2. Glossary 135 3. Documentation of equivalence for
More informationThe Role of Comparative Analyses for Evaluation of Generic Drug-Device Combinations in an ANDA
The Role of Comparative Analyses for Evaluation of Generic Drug-Device Combinations in an ANDA K. Witzmann, MD Inhalation and Drug-Device Combination Products Team Office of Research and Standards, Office
More informationBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies Standard Approach Part I: Design and Conduct H. Rettig, Ph.D. LLC www.ivivc.com Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98
More informationabsorption - the movement of a drug from its site of administration to the bloodstream
Glossary absorption - the movement of a drug from its site of administration to the bloodstream active pharmaceutical ingredient (API) - the chemical in an administered drug that is responsible for its
More informationThe views and opinions expressed in the following PowerPoint slides are
Indications, Dosage and Administration, Clinical Studies, Clinical Pharmacology sections of a CCDS Presented by: Mary Jane Boyle Head, Worldwide Product Labeling Merck & Co., 13-October-2011 The views
More informationIn vivo predictive biopharmaceutics tools for oral drug delivery
In vivo predictive biopharmaceutics tools for oral drug delivery Bertil Abrahamsson, AstraZeneca and Mark McAllister, Pfizer Background non-absorbable drug complex complex formation drug in solid dosage
More informationFirst UNGAP meeting Food-Drug Interactions Regulatory Aspects
First UNGAP meeting Food-Drug Interactions Regulatory Aspects Leuven, 09 March 2018 Dr. Henrike Potthast HPt COST meeting, Leuven, BE 09 March 2018 Page 1 Disclaimer The presentation reflects the personal
More informationPublic Assessment Report Scientific discussion. Acetylsalicylsyra ABECE (acetylsalicylic acid) Asp no:
Public Assessment Report Scientific discussion Acetylsalicylsyra ABECE (acetylsalicylic acid) Asp no: 2016-1378 This module reflects the scientific discussion for the approval of Acetylsalicylsyra ABECE.
More informationSupporting information. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo
Supporting information Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo Greg Thurber 1, Katy Yang 1, Thomas Reiner 1, Rainer Kohler 1, Peter Sorger 2, Tim Mitchison
More informationPreclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator
S830 Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator Yue Chen, Raj Nagaraja, Kha Le, Penelope A Kosinski, Gavin Histen, Charles Kung, Hyeryun Kim, Chandra
More informationNON-CLINICAL LOCAL TOLERANCE TESTING OF MEDICINAL PRODUCTS
NON-CLINICAL LOCAL TOLERANCE TESTING OF MEDICINAL PRODUCTS Guideline Title Non-clinical Local Tolerance Testing of Medicinal Products Legislative basis Directive 75/318/EEC as amended Date of first adoption
More informationDRUG SAFETY EVALUATION
DRUG SAFETY EVALUATION DRUG SAFETY EVALUATION SHAYNE C. GAD A John Wiley & Sons, Inc., Publication This book is printed on acid-free paper. Copyright # 2002 by John Wiley and Sons, Inc., New York. All
More informationORAL BIOAVAILABILITY ASSESSMENT
ORAL BIOAVAILABILITY ASSESSMENT WILEY SERIES ON PHARMACEUTICAL SCIENCE AND BIOTECHNOLOGY: PRACTICES, APPLICATIONS, AND METHODS Series Editor: Mike S. Lee Milestone Development Services Mike S. Lee Integrated
More informationKEYWORDS: Pharmaceutical Engineering, Chemical Engineering, Pharmaceutical Industry, Master Degree, Graduate Studies.
International Conference on Engineering Education and Research Progress Through Partnership 2004 VŠB-TUO, Ostrava, ISSN 1562-3580 Core Courses and Core Activities in the Pharmaceutical Engineering Program
More informationAN ENGINEERING APPROACH TO BIOMEDICAL SCIENCES: ADVANCED TESTING METHODS AND PHARMACOKINETIC MODELING
AN ENGINEERING APPROACH TO BIOMEDICAL SCIENCES: ADVANCED TESTING METHODS AND PHARMACOKINETIC MODELING Gaetano Lamberti *, Sara Cascone, Giuseppe Titomanlio Dipartimento di Ingegneria Industriale, Università
More informationPharmaceutical Sciences
SRI International Biosciences From Idea to IND Research on Disease Mechanisms Drug Discovery Drug Metabolism, Pharmacokinetics, & Toxicology Services Pharmaceutical Sciences Preclinical Development Planning
More informationSupplementary exam work (Number, form, scope) Courses (type of teaching) Contact time. Winter semester
READING VERSION OF MODULE DESCRIPTIONS The module descriptions are not part of the Regulations; they are integrated into the First Amendment to the Module Catalog. IEW-M1.1 Principles in Toxicology Number
More informationOn applications of conservation laws in pharmacokinetics
On applications of conservation laws in pharmacokinetics S.Piekarski (1), M.Rewekant (2) Institute of Fundamental Technological Research Polish Academy of Sciences (1), Medical University of Warsaw, Poland
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE ON THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections 1 2 3 London, 16 March 2009 Doc. Ref.: EMEA/CVMP/016/00-Rev.1-CONSULTATION 4 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) 5
More informationSimcyp Limited, Sheffield, UK 2. Eli Lilly, Windlesham, UK 3. Academic Unit of Clinical Pharmacology, University of Sheffield, UK
Drug Metab. Pharmacokinet. 24 (1): 53 75 (2009). Review A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical
More informationSupplementary exam work (Number, form, scope) Courses (type of teaching) Contact time. Winter semester
IEW-M1.1 Principles in Toxicology Number of credit points (CP): 12 Introduction to general toxicology Foundations of toxicokinetics (ADME: absorption, distribution, metabolism, and excretion) Foundations
More informationINTER CHANGEABILITY and EQUIVALENCE. Where we are and what we still have to determine!
INTER CHANGEABILITY and EQUIVALENCE Where we are and what we still have to determine! Acknowledgement Joint presentation UNICEF/MSF/ICRC Cecile Mace Jean Michel Caudron Birgit Schmauser What do we mean
More informationLine extension of immediate release products
EMA/EGA Joint Workshop on the Impact of the Revised EMA Guideline on Modified Release Dosage Forms Line extension of immediate release products London, 30 th April 2014 Dr. Alfredo García Arieta Jefe de
More informationPRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016
PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 1 FROM DISCOVERY TO COMMERCIALIZATION At least 10 years on average Average spend of $1.4B Less than 12% of drugs entering Phase I are approved
More informationVICH GL52 on Bioequivalence: blood level bioequivalence study
1 2 3 12 December 2013 EMA/CVMP/VICH/751935/2013 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 6 VICH GL52 on Bioequivalence: blood level bioequivalence study Draft Draft agreed by VICH
More informationSUPPLEMENTARY INFORMATION
In format provided by Orchard et al. (SEPTEMBER 2011) Supplementary information S1 Sample MIABE file exemplifying data extracted from PMID: 20568778 Responsible Person or Role Contact Person Bryan K. S.
More informationCourse Curriculum for Master Degree in Pharmaceutical Technology
Course Curriculum for Master Degree in Pharmaceutical Technology The Master Degree in Pharmaceutical Technology is awarded by the Faculty of Graduate studies at Jordan University of Science and Technology
More informationPharmacology Lecture 5. Anticoagulants
Pharmacology Lecture 5 Anticoagulants General overview Anti-thrombotic Drugs Antiplatlets Anticoagulants Fibrinolytics Anticoagulants Indirect Thrombin Inhibitors Anti-thrombotic effect is exerted by interaction
More informationDrug Delivery Systems. Joab Chen & Kenneth Tsang
Drug Delivery Systems Joab Chen & Kenneth Tsang Drug Delivery How do we physically get drugs into our bodies? What are the various systems that are in use today? In the future? We as a class will determine
More information